The research areas related to Journal of Pharmacovigilance are divided as Pharmacoviglance, Pharma Risk Management, Adverse Drug Reactions, Medication Errors, Drug Monitoring, Pharmacoepidemiology, Causality assesment, Clinical Trials, Drug safety, Veterinary Pharmacovigilance, and Medical literature. pharmaceutical intervention safety, Advances in Drug lisencing, Clinical Pharmacoviglance, Advances in Drug, Oncology, Drug Development, Clinical Trials, Molecular Biology, Drug monitoring, Molecular Imaging and Drug Delivery Science welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published approximately 15 days after acceptance.
Submit manuscript at https://www.walshmedicalmedia.com/submissions/pharmacovigilance.html
A manuscript number will be e-mailed to the corresponding author within 72 hours.
Publication Ethics and Malpractice Statement
Journal Policy Regarding the NIH Mandate
Journal of Pharmacovigilance will support authors by posting the published version of articles by NIH grant-holders and European or UK-based biomedical or life sciences grant holders to PubMed and PubMed Central immediately after publication
Editorial Policies and Process
Journal of Pharmacovigilance editorial policy that encourages researchers to submit the original research, reviews and editorial observations as articles, well supported by tables and graphic representation.
Article Processing Charges (APC)
Journal of Pharmacovigilance is self-financed and does not receive funding from any institution/government. Hence, the Journal operates solely through processing charges we receive from the authors and some academic/corporate sponsors. The handling fee is required to meet its maintenance. Being an Open Access Journal, Journal of Pharmacovigilance does not collect subscription charges from readers that enjoy free online access to the articles. Authors are hence required to pay a fair handling fee for processing their articles. However, there are no submission charges. Authors are required to make payment only after their manuscript has been accepted for publication.
Average Article prorcessing time (APT) is 50 days
The basic article processing fee or manuscript handling cost is as per the price mentioned above on the other hand it may vary based on the extensive editing, colored effects, complex equations, extra elongation of no. of pages of the article, etc.
Journal of Pharmacovigilance is an open access journal. Each article published by the journal follows a specific format.
One of the authors of the article, who takes responsibility for the article during submission and peer review, should follow the instructions for submission and submit the manuscript. Please note that to facilitate rapid publication and to minimize administrative costs, Walsh Medical Media only accepts online submissions, and that there is an article-processing charge on all accepted manuscripts.
During submission, you will be asked to provide a cover letter, in which you should explain why your manuscript should be published in the journal and declare any potential competing interests. Please provide the contact details (name and email addresses) of two potential peer reviewers for your manuscript. These should be experts in their field who will be able to provide an objective assessment of the manuscript. The suggested peer reviewers should not have published with any of the authors of the manuscript within the past five years, should not be current collaborators and should not be members of the same research institution. Suggested reviewers will be considered along with potential reviewers recommended by the Editorial Board members.
A list of acceptable file formats appears below. Additional files of any type, such as movies, animations or original data files can also be submitted as part of the manuscript.
Here are the files required for submission :
The title page should:
Each table should be numbered and cited in sequence using Arabic numerals (i.e., Table 1, 2, 3, etc.). Titles for tables should appear above the table and be no longer than 15 words. They should be pasted at the end of the document text file, in A4 Portrait or Landscape format. These will be typeset and displayed as such in the final, published form of the article. Tables should be formatted using the ‘Table object’ in a word processing program to ensure that columns of data remain aligned when the file is sent electronically for review. Tables should not be embedded as figures or spreadsheet files. Larger datasets or tables too wide for a Landscape page can be uploaded separately, as additional files. Additional files will not be displayed in the final, laid-out PDF of the article, but a link will be provided to the files as supplied by the author.
Figures should be provided in a separate single .DOC, .PDF or .PPT file, with a resolution of at least 300 dpi and not be embedded in the main manuscript file. If a figure consists of separate parts, please submit a single, composite illustration page that includes all parts of the figure. There is no charge for the use of color figures. The figure legends should be included in the main manuscript text file at the end of the document, rather than as part of the figure file. For each figure, the following information should be provided: Figure numbers in sequence, using Arabic numerals, a title of 15 words maximum and a detailed legend of up to 300 words. Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder(s) to reproduce figures or tables that have previously been published elsewhere.
All Supplementary Information (figures, tables and Summary diagram/, etc.) is supplied as a single PDF file, where possible. File size within the permitted limits for Supplementary Information. Images should be a maximum size of 640 x 480 pixels (9 x 6.8 inches at 72 pixels per inch).
All references, including links, must be numbered consecutively, in square brackets, in the order in which they are cited in the text, and should be formatted in the National Library of Medicine style. Each reference must have an individual reference number. Please avoid excessive referencing. Only articles, datasets and abstracts that have been published or are in press, or are available through public e-print/preprint servers, may be cited. The author is responsible for obtaining permission to quote personal communications and unpublished data from cited colleagues. Journal abbreviations should follow Index Medicus/MEDLINE.
Citations in the reference list should include all named authors, up to the first 6, before adding ‘et al.’. Any in press articles cited within the references and necessary for the reviewers’ assessment of the manuscript should be made available if requested by the editorial office.
Walsh Medical Media only accepts manuscripts written in English. Spelling should be either U.S. English or British English, but not a mixture.
Walsh Medical Media will not edit submitted manuscripts language; thus, reviewers may advise rejection of a manuscript due to grammatical errors. Authors are advised to write clearly and simply, and to have their article checked by colleagues before submission. In-house copyediting will be minimal. Non-native speakers of English may choose to make use of our copyediting services.
For Original Articles, Methodology Articles and Reviews, there is no explicit limit on the length of papers submitted, but authors are encouraged to be concise. Commentaries and Case Reports should be between 800 and 1,500 words. Letters to the Editor should be between 1,000 and 3,000 words. There is also no restriction on the number of figures, tables, additional files or references that can be included. Figures and tables should be numbered in the order in which they are referenced in the text. Authors should include all relevant supporting data with each article.
The abstract of Original and Methodology Articles should not exceed 250 words and must be structured into Background, Methods, Results and Conclusions. For Reviews, please provide an unstructured, single paragraph summary of no more than 350 words, of the major points raised. For Commentaries and Case Reports, please provide a short, unstructured, single paragraph summary of no more than 150 words. For Letters to the Editor, please provide a short, unstructured, single paragraph summary of no more than 250 words.
Please minimize the use of abbreviations and do not cite references in the abstract. Please list your trial registration number after the abstract, if applicable.
Add a list of 3 to 10 keywords below the abstract.
The Accession Numbers of nucleic acid, protein sequences or atomic coordinates cited in the manuscript should be provided in square brackets and include the corresponding database name.
Submitted manuscripts will be evaluated initially by the editor-in-chief and an associate editor. A rapid, initial decision regarding whether to have a manuscript formally reviewed by two or more reviewers with appropriate expertise, or rejected without a formal review will be determined based on the quality, scientific rigor and data presentation/analysis of the manuscript. It is anticipated that approximately 70% of the submitted manuscripts will undergo formal review and 30% will be rejected without evaluation by external reviewers.
Electronic proofs will be sent as an e-mail attachment to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript and no changes will be made in the manuscript at the proof stage. Authors can freely download the PDF file. Hard copies of the documents are available on request. Please click on the link for the charges.
The Journal of Pharmacovigilance membership program, initiated to accomplish the vision of making Healthcare & Scientific Information Open Access, enables academic and research institutions, societies, groups, funding organizations and corporations to actively support Open Access in scholarly publishing and also support the participation of its representatives and students in International conferences.For Further details contact Editorial office
As a member of Publisher International Linking Association, PILA, Journal of Pharmacovigilance follows the Creative Commons Attribution License and Scholars Open Access publishing policies.
All works published by Journal of Pharmacovigilance are under the terms of the Creative Commons Attribution License. This permits anyone to copy, distribute, transmit and adapt the work provided the original work and source is appropriately cited.